N-(4-chlorophenyl)-3-(6-fluoro-1H-indazol-3-yl)benzenesulfonamide

ID: ALA4867966

PubChem CID: 164622333

Max Phase: Preclinical

Molecular Formula: C19H13ClFN3O2S

Molecular Weight: 401.85

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=S(=O)(Nc1ccc(Cl)cc1)c1cccc(-c2n[nH]c3cc(F)ccc23)c1

Standard InChI:  InChI=1S/C19H13ClFN3O2S/c20-13-4-7-15(8-5-13)24-27(25,26)16-3-1-2-12(10-16)19-17-9-6-14(21)11-18(17)22-23-19/h1-11,24H,(H,22,23)

Standard InChI Key:  KZSQYNDFBLBPPD-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   12.4230  -15.2377    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.8451  -14.6599    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   11.6337  -15.4492    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.2259  -10.8298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2247  -11.6493    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9328  -12.0583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9310  -10.4209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6396  -10.8262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6444  -11.6448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4244  -11.8933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9018  -11.2281    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.4167  -10.5688    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.6802  -12.6644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1351  -13.2748    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3916  -14.0499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1927  -14.2158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.7368  -13.6004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4774  -12.8277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5180  -10.4214    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.0478  -14.4945    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.5040  -15.1044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7061  -14.9358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1625  -15.5450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4186  -16.3219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2235  -16.4862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7636  -15.8758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8756  -16.9325    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  9  2  0
  8  7  2  0
  7  4  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12  8  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
 10 13  1  0
  4 19  1  0
 15  2  1  0
  2 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 21  1  0
 24 27  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4867966

    ---

Associated Targets(Human)

MAP2K4 Tchem Dual specificity mitogen-activated protein kinase kinase 4 (1051 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 401.85Molecular Weight (Monoisotopic): 401.0401AlogP: 4.82#Rotatable Bonds: 4
Polar Surface Area: 74.85Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 7.75CX Basic pKa: 1.69CX LogP: 4.56CX LogD: 4.43
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.51Np Likeness Score: -2.13

References

1. Kwong AJ, Pham TND, Oelschlager HE, Munshi HG, Scheidt KA..  (2021)  Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma.,  12  (10.0): [PMID:34676038] [10.1021/acsmedchemlett.1c00376]

Source